Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

PURPOSE: Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP. METHODS: GOG0209 was a phase...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Miller, David S., Filiaci, Virginia L., Mannel, Robert S., Cohn, David E., Matsumoto, Takashi, Tewari, Krishnansu S., DiSilvestro, Paul, Pearl, Michael L., Argenta, Peter A., Powell, Matthew A., Zweizig, Susan L., Warshal, David P., Hanjani, Parviz, Carney, Michael E., Huang, Helen, Cella, David, Zaino, Richard, Fleming, Gini F.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2020
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7676887/
https://ncbi.nlm.nih.gov/pubmed/33078978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01076
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares